Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Celecoxib
Drug ID BADD_D00410
Description Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.[A34124]
Indications and Usage Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA).[L7646] Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.[L7646] It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.[L7646] Celecoxib, in combination with [tramadol], is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.[L38949]
Marketing Status approved; investigational
ATC Code L01XX33; M01AH01
DrugBank ID DB00482
KEGG ID D00567
MeSH ID D000068579
PubChem ID 2662
TTD Drug ID D03RTS
NDC Product Code 77771-159; 80425-0167; 80425-0281; 0591-3985; 51552-1461; 53104-7533; 66651-919; 13668-310; 33342-156; 33342-157; 42571-145; 57582-212; 0025-1520; 61919-682; 62135-023; 63187-562; 65862-910; 68071-2626; 70518-3424; 0591-3982; 71335-2019; 71610-283; 75834-239; 76420-009; 76420-243; 80425-0038; 51927-5063; 54245-3392; 57582-032; 62512-0018; 65862-793; 16714-733; 42806-721; 43063-967; 46708-267; 50436-3984; 57582-211; 59762-1517; 67296-1847; 68071-4642; 69367-302; 70247-006; 71205-027; 71205-664; 0591-3983; 75834-237; 81288-021; 81288-023; 0591-3984; 55111-898; 65427-002; 65977-0052; 77777-115; 42571-143; 50090-4789; 50090-5178; 50228-159; 57582-214; 0025-1525; 68180-398; 70518-3204; 70518-3733; 71335-0292; 71335-1066; 72189-360; 72241-023; 55154-7646; 60687-447; 62135-021; 62135-022; 63187-301; 68071-2776; 68180-395; 68788-8197; 69117-0023; 70247-009; 71209-056; 75834-238; 77771-156; 80425-0040; 16714-732; 43063-825; 45865-970; 46708-269; 46708-270; 50268-168; 53002-2338; 59762-1516; 60505-3847; 60505-3849; 61919-360; 62332-141; 63187-079; 63629-3021; 63629-8156; 68071-2733; 69367-301; 70518-3292; 72789-259; 75834-236; 80425-0323; 81288-022; 47621-024; 65691-0048; 68724-1004; 0093-7166; 0093-7170; 50090-5638; 50436-3982; 51990-033; 60687-436; 60760-742; 61919-837; 62332-143; 63187-643; 65162-817; 65162-819; 68788-8206; 69097-422; 69097-423; 70518-1346; 71205-055; 71335-1804; 0615-8338; 72241-022; 72567-001; 80425-0096; 13668-441; 0093-7165; 33342-155; 42806-720; 45865-943; 50268-169; 62332-140; 65162-820; 65862-907; 67296-1600; 69117-0021; 70518-2748; 70934-469; 71209-054; 71335-0936; 80425-0142; 80425-0209; 64552-4032; 13668-442; 16714-731; 16714-734; 29300-157; 29300-374; 42571-144; 50228-158; 50436-3983; 51655-059; 51990-034; 55154-7645; 55700-613; 0025-1515; 59762-1515; 59762-1518; 60505-3848; 60760-649; 60760-823; 65162-818; 65862-908; 67296-1345; 71209-055; 72241-024; 72241-025; 77771-157; 0904-6502; 58159-067; 68981-025; 29300-158; 43063-669; 46708-268; 51655-437; 57582-213; 59385-055; 0025-1530; 60760-824; 62332-142; 65862-909; 67296-1608; 68180-399; 68788-7286; 69097-420; 69097-421; 69117-0020; 70247-007; 70247-008; 70934-978; 71209-057; 71335-0868; 80425-0037; 80425-0039; 80425-0321; 49706-1880; 62704-0046; 65015-882; 72761-022; 13668-307; 0093-7306; 29300-373; 42571-142; 42806-723; 43353-257; 50090-6380; 50228-156; 50228-157; 63187-633; 68180-396; 68788-7264; 69117-0022; 70518-2922; 71205-020; 71205-439; 71610-584; 72189-123; 77771-158; 81288-020; 0904-6503; 43744-071; 52048-1995; 33342-158; 42806-722; 51655-060; 51655-436; 51990-035; 53002-1338; 55700-607
UNII JCX84Q7J1L
Synonyms Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Celebrex | SC 58635 | SC-58635 | SC58635
Chemical Information
Molecular Formula C17H14F3N3O2S
CAS Registry Number 169590-42-5
SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nephritis allergic10.01.03.044; 20.05.01.0180.000075%-
Ovarian cyst ruptured16.04.03.006; 21.11.01.0150.000050%-
Pernicious anaemia01.03.01.003; 07.17.01.004; 10.04.01.0070.000050%-
Sleep disorder due to general medical condition, insomnia type19.02.04.004---
Urinary bladder haemorrhage20.03.01.023; 24.07.01.0860.000050%-
Small intestinal haemorrhage07.12.03.002; 24.07.02.0190.000050%
Intervertebral disc space narrowing15.10.01.0070.000169%-
Foot deformity15.10.03.0050.000134%-
Perforated ulcer08.03.06.0020.000050%-
Asthmatic crisis22.03.01.0180.000099%-
Iris neovascularisation06.07.06.001; 24.03.07.0120.000050%-
Abdominal wall haematoma07.16.05.005; 24.07.02.0390.000050%-
Skin plaque23.03.03.044---
Psychological trauma19.01.02.0170.000109%-
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.000124%-
Sensitivity to weather change08.01.03.0770.000194%-
Preterm premature rupture of membranes18.02.02.0160.000075%-
Internal haemorrhage24.07.01.0720.000050%-
Acute oesophageal mucosal lesion07.04.05.0080.000050%-
Axial spondyloarthritis10.04.04.024; 15.01.09.0050.000174%-
Drug effect less than expected08.06.01.036---
Drug effective for unapproved indication08.06.01.037; 12.09.02.0010.000219%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.001005%-
Fixed eruption08.01.06.025; 10.01.01.037; 23.03.05.0080.000124%-
Gait inability08.01.02.011; 17.02.05.0690.000318%-
Hypertensive urgency24.08.01.005---
Illness08.01.03.091---
Sacral pain15.03.04.023---
Spinal stenosis15.10.04.014; 17.10.01.0310.000050%-
Therapeutic product effect decreased08.06.01.050---
The 23th Page    First    Pre   23 24    Next   Last    Total 24 Pages